Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.
Twist Bioscience (TWST) has been awarded the Great Place to Work® Certification™, an accolade based on employee feedback regarding workplace culture and experience. This certification signifies Twist's commitment to fostering a positive work environment, even during challenges like the global pandemic. CEO Emily M. Leproust highlighted the importance of employees in driving growth and success. Twist offers competitive compensation, employee development, and robust family-friendly policies. The company specializes in synthetic DNA technology, impacting multiple sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has entered into a partnership with Kyowa Kirin Pharmaceutical Research, Inc. to discover novel antibodies targeting an undisclosed G protein-coupled receptor (GPCR). This collaboration utilizes Twist's unique 'Library of Libraries' for biologics discovery, enabling rapid antibody development. The partnership aims to enhance the efficiency and success rate of antibody therapeutics, leveraging Twist's scalable DNA manufacturing capabilities. An upfront payment was received, with Kyowa Kirin holding an option for development and commercial rights.
Twist Bioscience Corporation and Biotia have received Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This in vitro diagnostic test is designed to detect SARS-CoV-2 RNA with high sensitivity and analyze the entire viral RNA sequence, allowing for the identification of genetic variants. This assay is significant amid rising concerns over new viral mutations. The test enables batch processing of samples, enhancing public health responses against COVID-19. It is expected to be available for purchase soon.
Twist Bioscience Corporation (Nasdaq: TWST) announced positive preclinical data for GLP-1R antibodies from its proprietary GPCR libraries, showing effective blood glucose control. The data, published in mAbs, highlight 13 high-affinity GLP-1R antibodies that could have multiple clinical uses, including treatment for Type-2 diabetes. Notably, the antibody TB59-2 demonstrated a two-day half-life, indicating potential for once-weekly administration. CEO Emily M. Leproust emphasized collaboration with various partners to optimize antibody discovery.
Twist Bioscience Corporation (Nasdaq: TWST) has announced the shipment of new synthetic RNA reference controls for SARS-CoV-2 variants B.1.351 and P.1, as well as controls for the B.1.1.7 variant in a stabilized format. These products aim to enhance global surveillance efforts amid increasing vaccination rates. The company continues to provide essential tools to identify and monitor COVID-19 mutations, demonstrating commitment to public health. Twist's synthetic controls, based on specific SARS-CoV-2 variants, are designed to cover the full viral genome and are verified for accuracy.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Watchmaker Genomics to enhance research capabilities in high throughput sequencing applications. Their collaboration aims to facilitate innovations in oncology, inherited disease detection, and liquid biopsy assays. The first product will integrate Watchmaker's high-fidelity amplification technology into Twist's library preparation kits. Both companies focus on delivering exceptional products, optimizing workflows, and improving genomic studies quality through joint development initiatives.
Twist Bioscience Corporation (NASDAQ: TWST) has announced its participation in the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting scheduled for March 1-3, 2021. Key events include a workshop featuring customer presentations from Regeneron Genetics Center and HelioHealth, along with a poster presentation on Artificial Barcoded Libraries (ABLs) aimed at enhancing NGS sequencing. Twist's innovative DNA synthesis platform positions it at the forefront of synthetic biology, serving industries like healthcare and agriculture.
Twist Bioscience (NASDAQ: TWST) has launched the Twist NGS Methylation Detection System, an innovative tool for analyzing DNA methylation patterns. This system is designed for early cancer detection through blood tests, utilizing next-generation sequencing technology. Partnering with New England Biolabs, Twist's system overcomes challenges in traditional methylation detection by using EM-seq for sample preparation. Early access customer HelioHealth reports improved efficiency and accuracy in developing liquid biopsy tests for cancers. The system aims to enhance research capabilities and diagnostic accuracy in genomics.
